PMID- 27136447
OWN - NLM
STAT- MEDLINE
DCOM- 20160922
LR  - 20220310
IS  - 2044-4052 (Print)
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 6
IP  - 5
DP  - 2016 May 2
TI  - Comparative evaluation of the therapeutic effect of metformin monotherapy with 
      metformin and acupuncture combined therapy on weight loss and insulin sensitivity 
      in diabetic patients.
PG  - e209
LID - 10.1038/nutd.2016.16 [doi]
AB  - OBJECTIVE: Obesity induces insulin resistance (IR), the key etiologic defect of 
      type 2 diabetes mellitus (T2DM). Therefore, an incidence of obesity-induced 
      diabetes is expected to decrease if obesity is controlled. Although Metformin is 
      currently one of the main treatment options for T2DM in obese patients, resulting 
      in an average of 5% weight loss, adequate weight control in all patients cannot 
      be achieved with Metformin alone. Thus, additional therapies with a weight loss 
      effect, such as acupuncture, may improve the effectiveness of 
      Metformin.Subjective:We designed this randomized clinical trial (RCT) to compare 
      the effects of Metformin monotherapy with that of Metformin and acupuncture 
      combined therapy on weight loss and insulin sensitivity among overweight/obese 
      T2DM patients, to understand whether acupuncture plus Metformin is a better 
      approach than Metformin only on treating diabetes. To understand whether 
      acupuncture can be an insulin sensitizer and, if so, its therapeutic mechanism. 
      RESULTS: Our results show that Metformin and acupuncture combined therapy 
      significantly improves body weight, body mass index (BMI), fasting blood sugar 
      (FBS), fasting insulin (FINS), homeostasis model assessment (HOMA) index, 
      interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), leptin, adiponectin, 
      glucagon-like peptide-1 (GLP-1), resistin, serotonin, free fatty acids (FFAs), 
      triglyceride (TG), low-density lipoprotein cholesterol (LDLc), high-density 
      lipoprotein cholesterol (HDLc) and ceramides. CONCLUSIONS: Consequently, 
      Metformin and acupuncture combined therapy is more effective than Metformin only, 
      proving that acupuncture is an insulin sensitizer and is able to improve insulin 
      sensitivity possibly by reducing body weight and inflammation, while improving 
      lipid metabolism and adipokines. As a result, electro-acupuncture (EA) might be 
      useful in controlling the ongoing epidemics in obesity and T2DM.
FAU - Firouzjaei, A
AU  - Firouzjaei A
AD  - Key Laboratory of Acupuncture and Medicine Research of Minister of Education, The 
      Second Clinical School, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Li, G-C
AU  - Li GC
AD  - Epidemiology and Biostatistics Department, Nanjing University of Chinese 
      Medicine, Nanjing, China.
FAU - Wang, N
AU  - Wang N
AD  - Key Laboratory of Acupuncture and Medicine Research of Minister of Education, The 
      Second Clinical School, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Liu, W-X
AU  - Liu WX
AD  - Key Laboratory of Acupuncture and Medicine Research of Minister of Education, The 
      Second Clinical School, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Zhu, B-M
AU  - Zhu BM
AD  - Key Laboratory of Acupuncture and Medicine Research of Minister of Education, The 
      Second Clinical School, Nanjing University of Chinese Medicine, Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160502
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
RN  - 0 (Adiponectin)
RN  - 0 (Biomarkers)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Insulin)
RN  - 0 (Interleukin-6)
RN  - 0 (Leptin)
RN  - 0 (Resistin)
RN  - 0 (Triglycerides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 333DO1RDJY (Serotonin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - *Acupuncture Therapy
MH  - Adiponectin/blood
MH  - Adult
MH  - Biomarkers/blood
MH  - Body Mass Index
MH  - Body Weight
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Diabetes Mellitus, Type 2/blood/*therapy
MH  - Fatty Acids, Nonesterified/blood
MH  - Female
MH  - Glucagon-Like Peptide 1/blood
MH  - Humans
MH  - Insulin/blood
MH  - *Insulin Resistance
MH  - Interleukin-6/blood
MH  - Leptin/blood
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Obesity/blood/complications/therapy
MH  - Resistin/blood
MH  - Serotonin/blood
MH  - Triglycerides/blood
MH  - Tumor Necrosis Factor-alpha/blood
MH  - Weight Loss/*drug effects
PMC - PMC4895377
EDAT- 2016/05/03 06:00
MHDA- 2016/05/03 06:01
PMCR- 2016/05/01
CRDT- 2016/05/03 06:00
PHST- 2015/10/07 00:00 [received]
PHST- 2016/01/01 00:00 [revised]
PHST- 2016/02/08 00:00 [accepted]
PHST- 2016/05/03 06:00 [entrez]
PHST- 2016/05/03 06:00 [pubmed]
PHST- 2016/05/03 06:01 [medline]
PHST- 2016/05/01 00:00 [pmc-release]
AID - nutd201616 [pii]
AID - 10.1038/nutd.2016.16 [doi]
PST - epublish
SO  - Nutr Diabetes. 2016 May 2;6(5):e209. doi: 10.1038/nutd.2016.16.